Introduction
The increasing mean lifespan of the population is a big success story of humanity, but also poses a challenge that industrialized countries are currently facing, since aging is associated with increased susceptibility to many diseases like cancer, type 2 diabetes, neurodegenerative disorders and steatohepatitis. Aging is considered to be caused by limitations in somatic maintenance as a tradeoff to reproduction, resulting in an accumulation of molecular and consequently tissue and organ damage over time [1] . Multiple mechanisms that cause or promote damage to macromolecules, cells and tissues, kept at bay by an equal number of mechanisms counteracting, pre-venting and repairing damage, have to be elucidated to develop a complete understanding of the aging process.
One prominent mechanism strongly related with cellular aging is cellular senescence. Senescence represents a permanent growth arrest induced by telomere attrition, oncogenic or environmental stress that functions a tumor-suppressor mechanism. Besides, senescent cells are now increasingly appreciated for their role in embryonic development, wound healing and tissue repair [2] . However, as senescent cells accumulate during lifetime, they exert detrimental effects on tissue function, contribute to chronic inflammatory states, and thus contribute to tissue, organ and organismal aging [3] , and removal of naturally occurring senescent cells in the mouse postpones the development of age-related pathologies and extends the lifespan [4] .
However, precise molecular understanding is still scarce, especially concerning miRNAs, which have been established as an important layer of gene expression control and might represent an attractive target for interventions aiming at healthy aging. Biogenesis, function and mechanisms of action of miRNAs are reviewed in great detail (e.g. [5] ). In brief, one miRNA is able to regulate up to hundred mRNA targets and therefore potentially orchestrates a large variety of cellular processes similar to transcription factors [6, 7] , contributing even to a potential posttranscriptional operon concept [8] .
The miR-17-92 cluster comprises some of the beststudied miRNAs so far. This cluster contains 6 miRNA members with overlapping and specific roles. Here, we focus on miRNA-17-5p and its role in aging, age-related diseases and cancer, emphasizing the emerging role of 'longevimiR'-17 in cellular and organismal aging.
Transcriptional Regulation and Target mRNAs

Conservation and Regulation of the miRNA-17-92 Cluster
The miR-17-92 cluster is located in the locus of the nonprotein-coding gene MIR17HG on chromosome 13. The miR-17-92 transcript spans 800 nucleotides within its host gene and comprises six miRNAs -miR-17-5p, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1. Its sequence is highly conserved among vertebrates [9] , especially in the seed region ( fig. 1 a) , as also shown by phylogenetic tree analysis ( fig. 1 b) . No homologues are found in nonvertebrates so far according to miRbase [10] .
In addition, paralogous versions of miR-17 have arisen by intragenomic gene duplication in the miR-106a-363 and miR-106b-25 clusters. While the seed regions are well conserved ( fig. 1 c) , differences in the 3 ′ and 5 ′ regions suggest overlapping, but different sets of target mRNAs and thus functions. How is the miR-17-92 cluster regulated on a transcriptional level? So far, several regulators of miR-17-92 transcription have been described. c-Myc, the cellular homolog of the retroviral v-myc oncogene, is a well-studied proto-oncogene. Besides regulating transcription of a plethora of protein-coding genes, c-myc activates the miR-17-92 cluster and represses a dozen of other miRNAs. Interestingly, a number of c-myc transcriptional targets ( fig. 2 ), like RPS6KA5 (ribosomal protein S6 kinase, 90 kDa, polypeptide 5), BCL11B (B-cell CLL/lymphoma 11B), PTEN (phosphatase and tensin homolog), E2F1 (E2F transcription factor 1) and HCFC2 (host cell factor C2) are also predicted targets of the miR-17-92 cluster [11] , which suggests a delicate regulatory mechanism by which c-myc simultaneously activates transcription and restricts abundance of respective mRNAs.
A similar mechanism is thought to be at work between Aurora Kinase A (AURKA), the miR-17-92 cluster and the transcription factor E2F1. AURKA is a serine/threonine kinase essential for regulation of mitosis and is overexpressed in many cancers. AURKA stabilizes the transcription factor E2F1 by inhibiting its proteasomal degradation ( fig. 2 ) , which again induces miR-17-92 transcription [12] and is at the same time its target. p53 acts as negative transcriptional regulator of the miR-17-92 cluster. Under hypoxia, p53 represses miR-17-92 transcription and thereby sensitizes cells for hypoxia-induced apoptosis, while overexpression of the miR-17-92 cluster inhibits apoptosis under hypoxia [13] .
Results of the ENCODE (Encyclopedia of DNA Elements) project further revealed that along with these experimentally confirmed transcription factors, BCL3 (Bcell CLL/lymphoma 3), IRF1 (interferon regulatory factor 1), SP1 (Sp1 transcription factor), TAL1 (T-cell acute lymphocytic leukemia 1) and ZBTB33 (zinc finger and BTB domain containing 33) might regulate the miR-17-92 cluster ( fig. 2 ) and are also targeted by individual miRNAs of the cluster [14] .
On the posttranscriptional level, several studies find that the miR-17-92 cluster members are not expressed to equal degrees in cells and tissues as would be expected from their joint transcription as a primary miRNA. This might be due to factors that differentially protect or degrade the single miRNA members after the pre-miRNA status, as it has been published for miR-18 [15] . However, so far, no such reports exist on miR-17-5p. In terms of Sequence similarities of miR-17-5p. a Phylogenetic comparison of miR-17-5p shows almost 100% sequence identity in monkey and gorilla and a high degree of similarity down to Zebra fish. b miR-17-5p is conserved among vertebrates. The numbers in the phylogenetic tree indicate the evolutionary distance between the organisms. c miR-17-5p has two homologous miRNAs encoded in the miR-106a-363 and miR-106b-25 clusters. The consensus sequence of these 3 seed family members, i.e. mature sequences with identical seed region, is shown.
tissue and cell type specificity, miR-17-5p is expressed ubiquitously and highly in all tissues tested so far [16] , pointing to a generally high importance of this miRNA.
Target mRNAs of the miR-17-92 Cluster and miR-17-5p
PTEN and E2Fs were the first confirmed targets of the miR-17-92 cluster in the context of cell cycle progression and apoptosis [17] . By now, a multitude of targets of the miR-17-92 cluster have been reported including members of the TGFβ (transforming growth factor-β) signaling pathway [18] . In addition, it also targets specific chromatin regulatory genes, such as Sin3b (SIN3 transcription regulator family member B; a transcriptional repressor for MYC-responsive genes), Hbp1 (HMG-box transcription factor 1; a transcriptional repressor that negatively regulates the Wnt-mediated beta catenin signaling pathway), Suv420h1 (suppressor of variegation 4-20 homolog 1; a histone methyltransferase, targeted to histone H3 by retinoblastoma proteins), and Btg1 (B-cell translocation gene 1, antiproliferative; a regulator of cell growth and differentiation), as well as the apoptosis regulator Bim (Bcl-2 interacting mediator of cell death; an activator of neuronal and lymphocyte apoptosis) [19] and the cell cycle inhibitor p21 ( fig. 2 ) [20] . Hence, miR-17-92 seems to maintain cell proliferation and survival, which might result in a neoplastic or progenitor/regenerative state of cells [19] . A series of mouse strains with targeted deletions of individual miR-17-92 members and subsequent phenotypic and gene expression analysis have recently provided a detailed picture of how miR-17-92 affects gene expression in vivo [21] .
In the following, we recapitulate data that point to a dual role of this cluster that might well result in an antagonistic pleiotropic function of miR-17-5p in young versus elderly individuals.
Aging, the miR-17-92 Cluster, and miR-17-5p
Aging-and Senescence-Dependent Regulation of miR-17-5p
In recent years, the important role of miRNAs in aging became increasingly evident [22] . In an effort to identify miRNAs commonly regulated during aging, microarray studies were performed comparing four human replicative cell-aging models -endothelial cells, skin fibroblasts, T-cells and renal proximal tubular epithelial cells -as well as three organismal aging models comprising skin, Tcells and mesenchymal stem cells. These very different model systems shared a set of commonly downregulated miRNAs, among them members of the miR-17-92 cluster including miR-17-5p, miR-19b, miR-20a and miR-106a [23] . Several studies using different model systems have confirmed the downregulation of the miR-17-92 cluster during aging [24] , and its upregulation in centenarians who are considered successful agers [25, 26] .
These expression changes are recapitulated by stressinduced senescence, as microarray data revealed that members of the miR-17-92 cluster, including miR-17-5p, are downregulated in stress-induced senescence of human diploid fibroblasts and human trabecular meshwork cells [27] . Figure 3 a gives an overview over up-and downregulation of miR-17-5p expression during aging and age-related diseases.
A Long-Lived Pre-miR-17-Overexpressing Mouse Model
The interest in the role of miR-17-5p in aging research has peaked with the report that its overexpression in mouse extends the organismal lifespan by approximately 16% [28] . This finding was somewhat surprising after the same authors had previously observed that miR-17 represses fibronectin expression, leading to cellular defects, growth retardation, smaller organs and strongly reduced hematopoietic cell lineages in miR-17-overexpressing mice [29] , results that do not seem well reconciled yet.
However, in favor of its life-prolonging role, miR-17-5p targets IRS1 (Insulin Receptor Substrate 1) and ADCY5 (Adenylate Cyclase 5), which modulate a complex signaling network, leading to upregulation of genes involved in autophagy and repressing senescence and apoptosis ( fig. 3 b) [28] .
To be more precise, IRS1 on the one hand activates AKT, which suppresses the mTOR inhibitor AMPK. Therefore, miR-17-5p-dependent silencing of IRS1 abrogates AMPK suppression, enabling mTOR inhibition and thus activating autophagy. On the other hand, IRS1 promotes expression of FOXO3A (forkhead box O3) and LC3-β (microtubule-associated protein 1 light chain 3 beta), which also enhance autophagy. At the same time, repression of miR-17-5p's direct target ADCY5 leads to translocation of RGS2 (regulator of G-protein signaling 2) from the membrane into the nucleus, where it interacts with and activates transcription of MKP7 (mitogen-activated protein kinase phosphatase 7). The MKP7 protein dephosphorylates PRAS40 (40-kDa proline-rich AKT substrate) and mTOR (mechanistic target of rapamycin), which thereupon bind each other, resulting in a suppression of mTOR activity that in consequence leads to attenuation of protein synthesis and stimulation of autophagy, resulting in reduced senescence. In fact, miR-17 transgenic mice exhibited increased bone mass and decreased presence of senescent cells in the skin, intestine, lung and heart. In addition, MKP7 acts as a negative regulator of c-Jun amino-terminal kinase and extracellular signal-regulated kinase (ERK) pathways. ERKs function in the control of cell division, and inhibitors of these enzymes are potential anticancer agents, hence miR-17-5p might also extend the organismal life span by reducing cancer risk, but that is still subject to speculation, since -as stated abovemiR-17 transgenic mice develop liver tumors [28] . The authors do not give any information about the causes of death in their miR-17 mice, and a potential confounder might be that both miR-17-5p and miR-17-3p are expressed from the pre-miR-17 construct to a comparable degree, and hence the relative effect of each specific miRNA to the observed organismal phenotype cannot be determined [28] .
Only few other miRNAs have been described to postpone cellular or organismal aging, one of them being inhibition of miR-21 in endothelial cell senescence [30] . Since elongation of the life span is still considered the golden standard for proving an activity in the aging process, we suggest tagging such miRNAs with the label 'longevi-miR'.
Cardiac Function and miR-17-5p
In transgenic mice, miR-17-5p is upregulated in damaged heart regions after induced infarction. It directly targets two inhibitors of matrix metalloproteases (MMPs), TIMP1 (tissue inhibitor of metalloproteinases 1) and TIMP2 (tissue inhibitor of metalloproteinases 2), leading to matrix remodeling after infarction [31] . In turn, miR-17 inhibition in a mouse model in vivo decreased MMP activity, enhanced cardiac function and helped prevent heart failure after infarction. Similarly, miR-17-5p is protective in a kidney ischemia-reperfusion model [32] .
In addition, overexpression of pre-miR-17 in mouse cardiac fibroblasts enhances cell survival upon oxidative stress, increases proliferation and reduces senescenceassociated β-galactosidase staining [33] , whereby the miR-17-3p component of the pre-miR-17 activates a transcriptional program that promotes epithelial-to- Fig. 3 . miR-17-5p in aging and age-related diseases. a Overview of miR-17-5p expression levels during aging and age-related pathologies. ↑ and ↓ designate up-and downregulation, respectively. b Relationship between miR-17-5p and mTOR, a central regulator of autophagy and apoptosis. miR-17-5p targets ACDY5, causing translocation of the GTPase activator RGS2 from the membrane to the nucleus, where it induces expression of MKP7. MKP7 dephosphorylates mTOR, which thereupon dimerizes with PRAS40 and is inactivated. Inhibitory phosphorylation of the ULK1-ATG13-FIP200 heterotrimer by mTOR is consequently abolished and activating phosphorylation catalyzed by AMPK. Consequently, the ULK1 complex activates autophagy, which in turn attenuates senescence and apoptosis. Simultaneously, miR-17-5p targets IRS1. IRS1 can activate AKT via PI3K, and AKT inhibits the autophagy activator AMPK. Therefore, IRS1 downregulation by miR-17-5p activates autophagy via two pathways. AKT = Proto-oncogene c-Akt; AMPK = AMP-activated protein kinase; ATG13 = autophagy related 13; FIP200 = focal adhesion kinase family kinase-interacting protein of 200 kDa; IRS1 = insulin receptor substrate 1; MKP7 = mitogen-activated protein kinase phosphatase 7; PRAS40 = 40-kDa proline-rich AKT substrate; RISC = RNA-induced silencing complex; ULK1 = Unc-51 like autophagy activating kinase 1.
Dellago/Bobbili/Grillari 26 mesenchymal transition and self-renewal while suppressing senescence, and might even act as a miR-17-5p antagomiR.
In summary, miR-17-5p and -3p play a role in cardiac aging in transgenic mice and cells in vitro. Again, both miR-17-5p and miR-17-3p are expressed from the same pre-miR-17, and therefore the relative contribution of each miRNA to the observed phenotype is not clear.
Aging, the Bone and miR-17-5p
The miR-17-92 cluster plays an important role in bone formation, as knockout in mice results in reduced bone mineral content and reduced bone strength [34] . Furthermore, miR-17-5p overexpression promotes osteogenic differentiation of MSCs (mesenchymal stem cells) [35] . However, during aging and in pro-inflammatory diseases, miR-17-5p expression was observed low in MSCs, concomitant with compromised osteogenic differentiation [36] . miR-17 overexpression partially rescued this defect by repressing Smurf1 (Smad ubiquitin regulatory factor one) [37] and SMAD7.
Since low miR-17-92 expression is a hallmark of aging and senescence [23] , and senescent cells contribute to reduced osteogenesis [38, 39] , it might be speculated that it is involved in loss of bone mineral density in the elderly. However, data on senescence and bone disease are still scarce, while one hint into this direction is that telomerase-deficient mice lose bone mass, most probably due to the SASP (senescence-associated secretory phenotype) [40] .
miR-17-5p in the Aging
Brain Surprisingly, miR-17 expression is increased in the brains of old mice compared to young mice [41] , while the relative abundance of the majority of miRNAs tested decreased in the mouse brain during aging. The informative value of this study is limited, though, by the fact that data are based on pooled cDNA libraries derived from only 2 individuals for each condition. Such an unexpected increase might be interpreted in the context of astrogliosis. Astrogliosis (or reactive astrocytosis) is an abnormal increase in the number of astrocytes due to the destruction of nearby neurons. It can be observed in age-related neurodegenerative diseases like Alzheimer's disease [42] or after spinal cord injury (SCI), where it leads to glial scar formation and inhibits axonal regeneration. miR-17-5p is upregulated after SCI and contributes to astrocyte proliferation [43] and hence potentially also to the astrogliosis phenotype observed in age-related neurodegenerative diseases.
miR-17-5p and mTOR -A Connection between Proliferation, Cancer and Aging
One focus in research on interventions that slow aging is on the mammalian target of rapamycin (mTOR). Inhibition of mTOR is one of the few accepted and universal interventions in model organisms that extends the lifespan and postpones age-related diseases like cardiovascular diseases, cancer and diabetes, and mTOR inhibitors are widely used to treat these diseases. Inhibition of mTOR activates many pathways that upregulate autophagy. Thereby, it fulfills multiple purposes -the clearance of dysfunctional or unnecessary molecules or organelles, the provision of nutrients and the degradation of intracellular pathogens. Both normal and premature aging are accompanied by a decline in autophagic potential, and a lack of functional autophagy leads to tissue degeneration similar to that observed in aged tissue [44] . In addition, mTOR is a central coordinator of cell proliferation whose function is deregulated in many cancers. Therefore, inhibitors of mTOR like rapamycin and its analogues are potential antitumor agents, some already approved for clinical use in cancer therapy.
Given its importance in cell physiology and tissue maintenance, it comes as no surprise that the mTOR pathway is subject to regulation by miRNAs, among them also the miR-17-92 cluster [45] .
As shown in figure 3 b, inhibition of mTOR by miR-17-5p upregulates autophagy and slows down the aging process in the mouse model presented by Du et al. [28] , discussed in the section A Long-Lived Pre-miR-17 Overexpressing Mouse Model. Indeed, oncogenic miRNAs like miR-17 are upregulated in rapamycin-resistant cells and inhibition of miR-17 restored rapamycin sensitivity. Thus, inhibitors of miR-17 could potentially serve as adjuvants in chemotherapy. However, it becomes clear from these studies that miR-17-5p is at the crossroads between aging and cancer.
miR-17-5p and Its Role in Cancer
In general, miR-17-5p is considered as an oncogene, supported by a large body of evidence from many different tumors. However, it might also be 'guilty-by-association' with its oncogenic miR-17-92 cluster members [46] , especially miR-19, which has been postulated as having the highest oncogenic potential [47] . By now, a more differentiated view has emerged in literature, where miR-17-5p alone possesses metastasis suppressor functions [48] . In addition, it seems to suppress cancer growth by stimu-lating T cells [49] . Finally, high circulating levels of miR-17-5p have been found in serum of patients suffering of several different types of cancer [50, 51] , suggesting that high levels of circulating miR-17-5p might serve as an alarm signal, or 'alarmiR'.
In sum, the effect of miR-17-5p varies according to cancer type, model system, and probably also to the relative expression levels of miR-17-3p and miR-17-5p, depending on the constructs used for overexpression and knockdown. The tumor-suppressive and tumorigenic properties of the miR-17-92 cluster are summarized in more detail in other recent reviews, e.g. [52, 53] .
Conclusion
In this review, we focused on the role of miR-17-5p in cellular senescence, aging and age-related diseases and opposed this role to cancer. miR-17-5p plays a major role in regulating many genes involved in autophagy, apoptosis and cell cycle regulation. Its overexpression in the mouse model extends the lifespan by promoting autophagy, and hence we suggest terming miR-17-5p the first 'longevi-miRNA'. At the same time, circulating miR-17-5p levels turned out to be high in almost all cancers, atherosclerosis and obesity, and might act as a biomarker or alarming signal, meriting the designation 'alarmiR-17'. While miR-17-5p is ubiquitously expressed, its biological function seems very cell, tissue and disease specific, which accounts for the confusingly high number of reports suggesting it to have a dual role, as a tumor suppressor and as an oncogene. Not only miR-17-5p, but also miR-17-3p surprisingly plays a role as tumor suppressor and as oncogene, sometimes synergistically with miR-17-5p, sometimes independently. Therefore, more research is needed to understand the basic biology of miR-17-3p and miR-17-5p in order to establish them as prognostic, diagnostic and therapeutic targets for aging and age-related diseases as well as cancer.
